Binds Enzyme Patents (Class 424/146.1)
-
Patent number: 9072737Abstract: The invention relates to tPA mutant devoid of protease activity and uses thereof in compositions and methods for the treatment and prevention of pathologic conditions involving neurological injury or an ischemic disease or condition. More specifically, the invention relates to a Ser481 to Ala mutant of tPA and to compositions and combinations thereof for the treatment of stroke, acute brain injury and neurodegenerative disorders. The invention further provides methods and kits for the treatment of said disorders.Type: GrantFiled: March 16, 2009Date of Patent: July 7, 2015Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.Inventors: Abd Higazi, Nuha Hijazi
-
Publication number: 20150147338Abstract: Aspects of the invention provide methods for treatment of a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases. In particular, aspects of the invention relate to the use of a therapeutic formulation comprising a galacto-rhamnogalacturonate for the treatment of a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases.Type: ApplicationFiled: June 6, 2013Publication date: May 28, 2015Inventors: Peter G. Traber, Eliezer Zomer, Anatole A. Klyosov
-
Patent number: 9040052Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.Type: GrantFiled: September 18, 2014Date of Patent: May 26, 2015Assignee: Kymab LimitedInventor: Jasper Rupert Clube
-
Publication number: 20150140005Abstract: There is provided a method of treating an inflammatory response to infection and complications associated therewith, by administering a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor to a subject, in need thereof. There is also provided a method of treating or preventing treating or preventing renal failure; renal dysfunction; respiratory failure; respiratory dysfunction; or acute lung injury. Provided herein are uses, pharmaceutical compositions, and commercial packages associated therewith.Type: ApplicationFiled: May 17, 2013Publication date: May 21, 2015Inventors: Keith R. Walley, John H. Boyd, James A. Russell
-
Patent number: 9034331Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.Type: GrantFiled: September 18, 2014Date of Patent: May 19, 2015Assignee: Kymab LimitedInventor: Jasper Rupert Clube
-
Patent number: 9034332Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.Type: GrantFiled: October 6, 2014Date of Patent: May 19, 2015Assignee: Kymab LimitedInventor: Jasper Rupert Clube
-
Publication number: 20150132317Abstract: Methods and compositions for treating neuroblastoma are disclosed.Type: ApplicationFiled: January 28, 2015Publication date: May 14, 2015Inventors: Yael P. Mosse, Erica L. Carpenter
-
Patent number: 9028825Abstract: A brain damage-related disorder is diagnosed in a subject by detecting at least one polypeptide, or a variant or mutant thereof, in a sample of body fluid taken from the subject, wherein the polypeptide is one for which the level is either increased or decreased in cerebrospinal fluid from deceased patients compared to cerebrospinal fluid from healthy donors.Type: GrantFiled: July 14, 2006Date of Patent: May 12, 2015Assignee: Universite de GeneveInventors: Denis Francois Hochstrasser, Jean-Charles Sanchez
-
Patent number: 9023359Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.Type: GrantFiled: July 15, 2014Date of Patent: May 5, 2015Assignee: Kymab LimitedInventor: Jasper Rupert Clube
-
Patent number: 9017681Abstract: The present invention relates to a method of preventing or treating a disease caused by bacterial infection by administering an effective amount of a modulator of bacterial adenylyl cyclase. The invention also provides pharmaceutical compositions useful for preventing or treating a disease, with the compositions containing a therapeutically effective amount of a modulator of bacterial adenylyl cyclase. The invention also provides screening methods for identifying selective modulators of bacterial adenylyl cyclase that do not substantially modulate adenylyl cyclase of the subject. The invention also provides methods for culturing bacterial pathogens and methods for inducing the pathogenic state in vitro.Type: GrantFiled: January 11, 2008Date of Patent: April 28, 2015Assignee: Cornell Research Foundation, Inc.Inventors: Lonny Levin, Jochen Buck, Leo Brizuela, Michael Pinnisi
-
Publication number: 20150110802Abstract: Methods are provided for producing a plurality of antibody species in a single animal, comprising delivering a plurality of antigen species to a single animal, where each antigen species is delivered to the animal at an anatomically distinct location. Also provided are methods for generating an immune response in an animal, where each antigen species is delivered to the animal at an anatomically distinct location, under conditions in which the animal produces a plurality of antibody species, where each antibody species specifically binds to a different antigen species among the plurality of antigen species.Type: ApplicationFiled: February 26, 2013Publication date: April 23, 2015Applicant: Medlmmune, LLCInventors: Partha S. Chowdhury, Chew-Shun Chang
-
Publication number: 20150098938Abstract: Compositions of modulators of acyl-CoA lysocardiolipin acyf transferase 1 (ALCAT1) expression, function or activity are provided. In particular, inhibitors of ALCAT1 are useful in treating metabolic diseases, cardiac diseases and, in general diseases associated with mitochondrial dysfunction. Assays for identification of novel ALCAT1 modulators are provided.Type: ApplicationFiled: February 15, 2013Publication date: April 9, 2015Applicant: The Penn State Research FoundationInventor: Yuguang Shi
-
Patent number: 9000132Abstract: The invention provides isolated anti-Lp-PLA2 antibodies that bind to Lp-PLA2. The invention also encompasses compositions comprising an anti-Lp-PLA2 antibody. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Lp-PLA2 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Lp-PLA2 antibodies. The invention encompasses a method of producing the anti-Lp-PLA2 antibodies. Other aspects of the invention are a method of detecting an Lp-PLA2 in a subject.Type: GrantFiled: July 31, 2013Date of Patent: April 7, 2015Assignee: diaDexus, Inc.Inventors: Paul Levi Miller, Laura Corral
-
Patent number: 8999325Abstract: Disclosed are methods for treating eye diseases or conditions characterized by vascular instability, vascular leakage and neovacularization such as diabetic macular edema, age-related macular edema, choroidal neovascularization, diabetic retinopathy, trauma, ocular ischemia, retinal angiomatous proliferation, macular telangiectasia and uveitis.Type: GrantFiled: October 15, 2012Date of Patent: April 7, 2015Assignee: Aerpio Therapeutics, IncInventors: Kevin Peters, Robert Shalwitz
-
Patent number: 8999341Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.Type: GrantFiled: September 18, 2014Date of Patent: April 7, 2015Assignee: Kymab LimitedInventor: Jasper Rupert Clube
-
Patent number: 8992927Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.Type: GrantFiled: August 29, 2014Date of Patent: March 31, 2015Assignee: Kymab LimitedInventor: Jasper Rupert Clube
-
Patent number: 8986929Abstract: The present invention identifies genotypes associated with resistance to extrapyramidal symptoms induced by antipsychotic drugs. The present invention further identifies genotypes associated with predisposition to the onset or aggravation of extrapyramidal symptoms induced by antipsychotic drugs and use thereof for assessment of patient populations. Specifically, the present invention relates to particular polymorphisms in the RGS2 gene that are associated with resistance or susceptibility to drug-induced extrapyramidal symptoms.Type: GrantFiled: June 7, 2011Date of Patent: March 24, 2015Assignee: Hadasit Medical Research Services and Development Ltd.Inventors: Bernard Lerer, Lior Greenbaum
-
Patent number: 8986694Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.Type: GrantFiled: August 29, 2014Date of Patent: March 24, 2015Assignee: Kymab LimitedInventor: Jasper Rupert Clube
-
Publication number: 20150064134Abstract: The described invention provides compositions and methods for treating asthma, a disease, condition or pathologic process whose progression is characterized by one or more of aberrant fibroblast proliferation and extracellular matrix deposition producing constriction in an airway, airway remodeling, and airway obstruction in lung tissue. The method includes administering a pharmaceutical composition comprising a therapeutic amount of a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, wherein the therapeutic amount of the polypeptide is effective to reduce the constriction of small airway dimensions and airway obstruction, treat airway remodeling, or a combination thereof.Type: ApplicationFiled: August 29, 2014Publication date: March 5, 2015Inventors: Cynthia Lander, Colleen Brophy
-
Publication number: 20150050285Abstract: Combination therapy for cancer makes use of HSP27 inhibitors and EGFR tyrosine kinase inhibitors or antifolates.Type: ApplicationFiled: February 1, 2013Publication date: February 19, 2015Inventors: Martin E. Gleave, Amina Zoubeidi, Masafumi Kumano
-
Publication number: 20150044226Abstract: A monoclonal antibody that binds to a phospholipase D4 (PLD4) protein, or a fragment containing an antigen-binding region thereof.Type: ApplicationFiled: January 31, 2013Publication date: February 12, 2015Applicant: SBI Biotech Co., LtdInventors: Minkwon Cho, Tomohide Yamazaki, Mayuki Endo, Koji Ishida
-
Patent number: 8951523Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.Type: GrantFiled: March 28, 2014Date of Patent: February 10, 2015Assignee: Kymab LimitedInventor: Jasper Rupert Clube
-
Patent number: 8945563Abstract: The present invention concerns an antibody specific for human ALK (Anaplastic Lymphoma Kinase), in particular a scFv, a nucleic acid sequence encoding it, its production and its use as a pharmaceutical or for diagnostic purposes. Said antibody is suitable for the local treatment of tumors, in particular glioblastoma.Type: GrantFiled: January 31, 2011Date of Patent: February 3, 2015Assignee: Delenex Therapeutics AGInventors: Adrian Auf Der Maur, Alcide Barberis, Peter Lichtlen
-
Patent number: 8933202Abstract: The present invention refers to antibodies, particularly to monoclonal antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.Type: GrantFiled: November 12, 2008Date of Patent: January 13, 2015Assignee: U3 Pharma GmbHInventors: Thore Hettmann, Jens Niewöhner, Jens Ruhe, Peter Wirtz, Kerstin Selle, Esther Zwick-Wallasch, Mike Rothe
-
Patent number: 8926969Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.Type: GrantFiled: December 19, 2012Date of Patent: January 6, 2015Assignee: Takeda Pharmaceutical Company LimitedInventors: Kathleen Ann Elias, Gregory Landes, Shewta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
-
Patent number: 8916154Abstract: Disclosed are antibodies that specifically recognize ?5-desaturase, methods of producing the antibodies, nucleotides and polypeptides for producing the antibodies, and methods of using the antibodies. The ?5-desaturase-specific antibodies provide improved methods of detecting ?5-desaturase in a sample.Type: GrantFiled: January 13, 2010Date of Patent: December 23, 2014Assignee: Abbott LaboratoriesInventors: Tapas Das, Suzette L. Pereira, Pradip Mukerji, Padmavathy Krishnan
-
Publication number: 20140370010Abstract: The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of myeloproliferative disorders.Type: ApplicationFiled: August 29, 2014Publication date: December 18, 2014Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton, Varghese Palath
-
Publication number: 20140363435Abstract: The invention concerns uses of anti-KL? agents, and detection of KL? and/or FGF19 and/or FGFR4.Type: ApplicationFiled: June 12, 2014Publication date: December 11, 2014Applicant: GENENTECH, INC.Inventor: Luc Desnoyers
-
Publication number: 20140348850Abstract: The present invention relates to methods of reducing blood pressure in a subject by administering a plasma kallikrein inhibitor.Type: ApplicationFiled: August 15, 2014Publication date: November 27, 2014Inventors: Edward P. Feener, Allen Clermont
-
Publication number: 20140341927Abstract: The present invention concerns an antibody which specifically binds to an abnormal superoxide dismutase 1 (SOD1), and which neutralizes its pathologic effect when administered to an animal such as a human. The antibody of the invention is a monoclonal antibody produced by hybridoma cell lines deposited with the International Depositary Authority of Canada on Aug. 29, 2006 under accession numbers ADI-290806-01, ADI-290806-02 and ADS-290806-03. The present invention also concerns the use of the antibody of the invention in the treatment, prevention and diagnosis of neurodegenerative diseases such as Amyotrophic lateral sclerosis, Parkinson and Alzheimer in an animal such as a human.Type: ApplicationFiled: May 27, 2014Publication date: November 20, 2014Applicant: Universite LavalInventors: Jean-Pierre Julien, Makoto Urushitani
-
Patent number: 8883157Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.Type: GrantFiled: December 23, 2013Date of Patent: November 11, 2014Assignee: Kymab LimitedInventor: Jasper Rupert Clube
-
Patent number: 8877198Abstract: It is disclosed here a method for reducing phosphate absorption in a human or non-human animal subject wherein the subject consumes a diet containing phytic acid or phytate and either has or is at risk of developing hyperphosphatemia. The method includes the step of administering orally to the subject an anti-intestinal alkaline phosphatase antibody in an amount effective to reduce or maintain the serum phosphate concentration in the subject.Type: GrantFiled: October 23, 2007Date of Patent: November 4, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Mark Cook, Martin Petkovich, Christian Helvig, Erica Hellestad, Keith Crawford
-
Patent number: 8877900Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: GrantFiled: October 29, 2010Date of Patent: November 4, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Peter Peizhi Luo, Kevin Caili Wangr, Pingyu Zhong, Mark Hsieh, Yan Li, Xinwei Wang, Feng Dong, Andrei Golosov, Yan Ni, Weirong Wang, Laurence B. Peterson, Rose Cubbon, Sujata Sharma, Jon Condra, Jun Lu, Gopalakrishnan Parthasarathy, Stephen Soisson, Noel Byrne
-
Publication number: 20140314787Abstract: The present application provides a method for treating a neurodegenerative disease in a subject characterised in that the endoplasmic reticulum protein retrotranslocation machinery and/or VCP is modulated by administering to said subject a therapeutically effective amount of a modulator of said endoplasmic reticulum protein retrotranslocation machinery and/or of VCP.Type: ApplicationFiled: November 7, 2012Publication date: October 23, 2014Inventors: Pico Caroni, Francesco Roselli
-
Publication number: 20140314746Abstract: The invention includes novel methods of treating or preventing fibrosis in a subject afflicted with scleroderma, comprising administering to the subject a therapeutically effective amount of an agent that inhibits formation of at least one inflammasome signaling product in the subject.Type: ApplicationFiled: March 11, 2014Publication date: October 23, 2014Applicant: Philadelphia Health and Education Corporation, d/b/a Drexel University College of MedicineInventors: CAROL M. ARTLETT, PETER D. KATSIKIS
-
Publication number: 20140294854Abstract: The present invention provides compositions and methods for treating obesity in a subject by administering an inhibitor of UBE2L6 or an activator of adipocyte triglyceride lipase to the subject.Type: ApplicationFiled: March 8, 2012Publication date: October 2, 2014Applicant: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Streamson Coo Chua, Shun-Mei Liu, Genevieve Marcelin
-
Patent number: 8841424Abstract: The present invention refers to monoclonal humanized antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.Type: GrantFiled: May 11, 2010Date of Patent: September 23, 2014Assignee: U3 Pharma GmbHInventors: Peter Wirtz, Jens Ruhe, Takeshi Takizawa, Tomoko Takayama
-
Patent number: 8835111Abstract: The invention relates to methods of evaluating MS severity based on analysis of single nucleotide polymorphisms (SNPs) and to products and kits for use in such methods.Type: GrantFiled: March 12, 2010Date of Patent: September 16, 2014Assignee: Brainco Biopharma S.L.Inventors: David Arteta, Marta Artieda, Diego Tejedor, Antonio Martinez, Laureano Simon, Bart A. Crusius, Salvador Pena, Madeleine Sombekke, Bernard Uitdehaag, Chris Polman
-
Patent number: 8828668Abstract: Compositions and methods are provided for prognostic classification of inflammatory diseases, e.g. inflammatory demyelinating disease, patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness. Assessment of this signature pattern thus allows improved methods of care. In one embodiment of the invention, the autoimmune disease is multiple sclerosis or neuromyelitis optica.Type: GrantFiled: February 11, 2011Date of Patent: September 9, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Robert C. Axtell, Lawrence Steinman, May H. Han, Brigit A. de Jong, Chander Raman, Michael Walker, Jing Shi
-
Patent number: 8828395Abstract: Hematopoietic-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof, as well as compositions comprising related agents such as antibodies and other binding agents. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of hematopoiesis.Type: GrantFiled: June 16, 2011Date of Patent: September 9, 2014Assignee: aTyr Pharma, Inc.Inventors: Jeffry Dean Watkins, Alain P. Vasserot, Rajesh Belani, Leslie Ann Greene, Ryan Andrew Adams
-
Patent number: 8821875Abstract: The present invention is based on the unexpected finding that, in addition to catalase, SOD is also involved in protecting tumor cells, wherein the inhibition effects of the two protective enzymes support one another in a complementary manner. The invention thus relates to pharmaceutical compositions containing at least two antibodies or the biologically active fragments thereof, wherein the one antibody is directed against the catalase and the other antibody is directed against the superoxide dismutase, as well as their use for treating a tumor disease.Type: GrantFiled: June 15, 2012Date of Patent: September 2, 2014Assignee: Universitaetsklinikum FreiburgInventor: Georg Bauer
-
Patent number: 8821874Abstract: Disclosed herein is a method of treating dry eye with a KLK-13 antibody.Type: GrantFiled: July 22, 2013Date of Patent: September 2, 2014Assignee: Allergan, Inc.Inventors: Michael E. Stern, Christopher S. Schaumburg, Karyn F. Siemasko, Jianping Gao
-
Publication number: 20140227284Abstract: Described herein are compounds, compositions and methods for treatment of cancer. Also described are methods and uses for identifying subject with cancer that are suitable for treatment with the compounds, composition and methods are described herein. In one aspect of the present invention, there is provided a method of treating a subject having a cancer deficient in NMT2, comprising: administering to said subject an NMT inhibitor.Type: ApplicationFiled: July 23, 2012Publication date: August 14, 2014Applicant: PACYLEX PHARMACEUTICALS INC.Inventors: Luc G. Berthiaume, Erwan Beauchamp, Conganige Maneka Anne Perinpanayagam, Chuiyee Yap
-
Publication number: 20140227279Abstract: Compositions and methods for the treatment of autoimmune and inflammatory diseases are disclosed.Type: ApplicationFiled: August 9, 2012Publication date: August 14, 2014Applicant: Lankenau Institute for Medical ResearchInventors: Lisa Laury-Kleintop, Laura Mandik-Nayak, George C. Prendergast, James Duhadaway
-
Patent number: 8802827Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: GrantFiled: October 29, 2010Date of Patent: August 12, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Peter Peizhi Luo, Kevin Caili Wang, Pingyu Zhong, Mark Hsieh, Yan Li, Xinwei Wang, Feng Dong, Andrei Golosov, Yan Ni, Weirong Wang, Laurence B. Peterson, Rose Cubbon
-
Patent number: 8778885Abstract: The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2). In certain embodiments, the invention provides methods of treating diseases such as Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis using amyotrophic disease-specific epitopes, and compositions including these epitopes. The invention also provides antibodies that bind to monomeric or misfolded SOD1, and not on the molecular surface of native homodimeric SOD1.Type: GrantFiled: June 8, 2011Date of Patent: July 15, 2014Assignee: Amorfix Life Sciences Ltd.Inventors: Neil R. Cashman, Avijit Chakrabartty, Rishi Rakhit, Joachim Bernhard Ostermann
-
Patent number: 8765126Abstract: The present embodiments relate to novel uses of MPO inhibitors and inhibitors of MPO and E-selectin binding. In some embodiments, methods are provided for treating G-CSF-induced vascular complications and associate tissue injury comprising administering to a subject in need thereof a compound that inhibits E-selectin receptor/ligand interaction or inhibits MPO activity. The inhibitors may be administered in conjunction with G-CSF therapy. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics (including aptamers) and organic compounds (e.g., glycomimetics).Type: GrantFiled: May 7, 2012Date of Patent: July 1, 2014Inventor: Robert Sackstein
-
Publication number: 20140178399Abstract: Certain embodiments are directed to compositions and methods of inhibiting pathogenic bacterial infection involving ADAMIO comprising administering an effective amount of a metalloprotease inhibitor to a patient. Certain embodiments are directed to method of inhibiting Staphylococcal infection comprising administering an effective amount of a metalloprotease inhibitor to a patient. Other embodiments concern methods of inhibiting infection by a bacteria from the genus Clostridium, Streptococcus, Listeria, Bacillus, or Arcanobacterium.Type: ApplicationFiled: November 9, 2011Publication date: June 26, 2014Applicant: University of ChicagoInventor: Juliane Bubeck Wardenburg
-
Patent number: 8728472Abstract: The present invention relates to a monoclonal antibody or fragment thereof, which binds specifically to the cyclin-dependent kinase 5 (Cdk5) activating protein, p25 and not to p35, a hybridoma cell line producing the monoclonal antibody, and methods for the detection and/or isolation of p25, p25 fragments or homologs thereof from biological material. The invention further relates to the use of the monoclonal antibody or fragment thereof for detection and treatment of neuronal disorders and cancers.Type: GrantFiled: June 3, 2010Date of Patent: May 20, 2014Assignee: The Board of Regents of the University of Texas SystemInventors: James A. Bibb, Janice W. Kansy
-
Patent number: 8722044Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.Type: GrantFiled: February 17, 2012Date of Patent: May 13, 2014Assignee: Janssen Biotech, Inc.Inventors: Juan Carlos Almagro, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou